Establishing a framework for best practices for quality assurance and quality control in untargeted metabolomics.

Guidance Liquid chromatography–mass spectrometry (LC-MS) Quality assurance (QA) Quality control (QC) Reproducibility Untargeted metabolomics

Journal

Metabolomics : Official journal of the Metabolomic Society
ISSN: 1573-3890
Titre abrégé: Metabolomics
Pays: United States
ID NLM: 101274889

Informations de publication

Date de publication:
12 Feb 2024
Historique:
received: 27 09 2023
accepted: 11 12 2023
medline: 12 2 2024
pubmed: 12 2 2024
entrez: 12 2 2024
Statut: epublish

Résumé

Quality assurance (QA) and quality control (QC) practices are key tenets that facilitate study and data quality across all applications of untargeted metabolomics. These important practices will strengthen this field and accelerate its success. The Best Practices Working Group (WG) within the Metabolomics Quality Assurance and Quality Control Consortium (mQACC) focuses on community use of QA/QC practices and protocols and aims to identify, catalogue, harmonize, and disseminate current best practices in untargeted metabolomics through community-driven activities. A present goal of the Best Practices WG is to develop a working strategy, or roadmap, that guides the actions of practitioners and progress in the field. The framework in which mQACC operates promotes the harmonization and dissemination of current best QA/QC practice guidance and encourages widespread adoption of these essential QA/QC activities for liquid chromatography-mass spectrometry. Community engagement and QA/QC information gathering activities have been occurring through conference workshops, virtual and in-person interactive forum discussions, and community surveys. Seven principal QC stages prioritized by internal discussions of the Best Practices WG have received participant input, feedback and discussion. We outline these stages, each involving a multitude of activities, as the framework for identifying QA/QC best practices. The ultimate planned product of these endeavors is a "living guidance" document of current QA/QC best practices for untargeted metabolomics that will grow and change with the evolution of the field.

Sections du résumé

BACKGROUND BACKGROUND
Quality assurance (QA) and quality control (QC) practices are key tenets that facilitate study and data quality across all applications of untargeted metabolomics. These important practices will strengthen this field and accelerate its success. The Best Practices Working Group (WG) within the Metabolomics Quality Assurance and Quality Control Consortium (mQACC) focuses on community use of QA/QC practices and protocols and aims to identify, catalogue, harmonize, and disseminate current best practices in untargeted metabolomics through community-driven activities.
AIM OF REVIEW OBJECTIVE
A present goal of the Best Practices WG is to develop a working strategy, or roadmap, that guides the actions of practitioners and progress in the field. The framework in which mQACC operates promotes the harmonization and dissemination of current best QA/QC practice guidance and encourages widespread adoption of these essential QA/QC activities for liquid chromatography-mass spectrometry.
KEY SCIENTIFIC CONCEPTS OF REVIEW UNASSIGNED
Community engagement and QA/QC information gathering activities have been occurring through conference workshops, virtual and in-person interactive forum discussions, and community surveys. Seven principal QC stages prioritized by internal discussions of the Best Practices WG have received participant input, feedback and discussion. We outline these stages, each involving a multitude of activities, as the framework for identifying QA/QC best practices. The ultimate planned product of these endeavors is a "living guidance" document of current QA/QC best practices for untargeted metabolomics that will grow and change with the evolution of the field.

Identifiants

pubmed: 38345679
doi: 10.1007/s11306-023-02080-0
pii: 10.1007/s11306-023-02080-0
pmc: PMC10861687
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

20

Subventions

Organisme : Carlos III Health Institute (Spain)
ID : CPII21/00003
Organisme : Fonds de Recherche du Quebec - Sante (FRQS)
ID : Chercheur Boursier Junior 2 grant 312947

Informations de copyright

© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

Metabolomics. 2018;14(6):72
pubmed: 29805336
Metabolomics. 2007 Sep;3(3):211-221
pubmed: 24039616
Plants (Basel). 2021 Nov 08;10(11):
pubmed: 34834772
Analyst. 2006 Oct;131(10):1075-8
pubmed: 17003852
Anal Bioanal Chem. 2013 Jun;405(15):5147-57
pubmed: 23455646
Metabolomics. 2017;13(1):1
pubmed: 27980501
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Feb 1;1164:122515
pubmed: 33460910
Drug Discov Today. 2022 Jun;27(6):1763-1773
pubmed: 35218927
Metabolomics. 2022 Aug 27;18(9):70
pubmed: 36029375
J Pharm Biomed Anal. 2018 Jan 5;147:149-173
pubmed: 28823764
Nucleic Acids Res. 2020 Jan 8;48(D1):D440-D444
pubmed: 31691833
Metabolites. 2022 Jul 23;12(8):
pubmed: 35893244
Anal Chem. 2023 Dec 26;95(51):18645-18654
pubmed: 38055671
J Proteome Res. 2022 Mar 4;21(3):590-598
pubmed: 34928621
Metabolomics. 2020 Oct 12;16(10):113
pubmed: 33044703
Nat Protoc. 2011 Jun 30;6(7):1060-83
pubmed: 21720319
Biochem J. 1984 Jan 15;217(2):365-75
pubmed: 6696735
Mol Biosyst. 2012 Feb;8(2):470-81
pubmed: 22041788
Anal Bioanal Chem. 2012 Jun;403(6):1523-48
pubmed: 22576654
Proc Natl Acad Sci U S A. 1971 Oct;68(10):2374-6
pubmed: 5289873
Anal Chem. 2021 Feb 2;93(4):1924-1933
pubmed: 33448796
Bioanalysis. 2020 Oct;12(20):1427-1437
pubmed: 33025797
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 1;1093-1094:80-81
pubmed: 29990717
J Proteome Res. 2007 Aug;6(8):3291-303
pubmed: 17625818
Metabolomics. 2019 Jan 3;15(1):4
pubmed: 30830465
Metabolomics. 2023 Nov 8;19(11):93
pubmed: 37940740
Nat Commun. 2019 Jul 10;10(1):3041
pubmed: 31292445
Xenobiotica. 1999 Nov;29(11):1181-9
pubmed: 10598751
Plant Mol Biol. 2002 Jan;48(1-2):155-71
pubmed: 11860207

Auteurs

Jonathan D Mosley (JD)

Center for Environmental Measurement and Modeling, Environmental Protection Agency, Athens, GA, 30605, USA. mosley.jonathan@epa.gov.

Tracey B Schock (TB)

Chemical Sciences Division, National Institute of Standards and Technology (NIST), Charleston, SC, 29412, USA.

Chris W Beecher (CW)

IROA Technologies, Chapel Hill, NC, USA.

Warwick B Dunn (WB)

Centre for Metabolomics Research, Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK.

Julia Kuligowski (J)

Neonatal Research Group, Health Research Institute La Fe, 46026, Valencia, Spain.

Matthew R Lewis (MR)

Life Sciences Mass Spectrometry Division, Bruker UK Limited, Coventry, CV4 8HZ, UK.
National Phenome Centre & Division of Systems Medicine, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, W12 0NN, UK.

Georgios Theodoridis (G)

BIOMIC_Auth, Center for Interdisciplinary Research and Innovation (CIRI-AUTH), Aristotle University Thessaloniki, 57001, Thermi, Greece.

Candice Z Ulmer Holland (CZ)

Eastern Laboratory, Office of Public Health Science (OPHS), Food Safety and Inspection Service (FSIS), Department of Agriculture (USDA), Athens, GA, 30605, USA.

Dajana Vuckovic (D)

Department of Chemistry and Biochemistry, Concordia University, Montreal, QC, H4B 1R6, Canada.

Ian D Wilson (ID)

Centre for Metabolomics Research, Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK.
Division of Systems Medicine, Department of Metabolism Department of Metabolism, Digestion and Reproduction, Imperial College, London, W12 0NN, UK.

Krista A Zanetti (KA)

Office of Nutrition Research, Office of the Director, Division of Program Coordination, Planning, and Strategic Initiatives, National Institutes of Health, Bethesda, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH